Fp MDPI

DRUG7 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

AsthmaPersistent Asthma

Phase 1

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

CompletedNCT06290102

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2024-05-16End: 2024-10-07Updated: 2025-08-14

Phase 2

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

CompletedNCT01479621

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2012-01-31End: 2013-07-31Updated: 2017-06-05

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

CompletedNCT01576718

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2012-04-30End: 2013-10-31Updated: 2018-05-08

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

CompletedNCT01772368

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2013-01-31End: 2013-06-30Updated: 2017-06-12

Phase 3

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

CompletedNCT02139644

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2014-06-30End: 2015-09-30Updated: 2021-11-12

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

CompletedNCT02141854

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2014-06-30End: 2015-09-30Updated: 2021-11-09

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

CompletedNCT02175771

Teva Branded Pharmaceutical Products R&D, Inc.Persistent Asthma

Start: 2014-07-31End: 2015-07-31Updated: 2021-11-09

Related Papers

Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.

2017-06-219 citations

A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma

Allergy and Asthma Proceedings2017-05-2514 citations

Safety, efficacy, and dose response of fluticasone propionate delivered via the novel MDPI in patients with severe asthma: A randomized, controlled, dose-ranging study

Journal of Asthma2016-10-247 citations

Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma

Allergy and Asthma Proceedings2016-05-2411 citations